At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,370 enrolled
Drug / intervention
indomethacin suppository +1 moredrug
Likely dose
indomethacin suppository 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)
In Brief
A Phase 4 clinical trial evaluating indomethacin suppository and Glycerin Suppository for Pancreatitis. Completed, enrolled 1,370 participants across 1 site.
Detailed Summary
The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatitis
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedJun 2016
Primary CompletionJul 2019
Study CompletionAug 2021
TodayJul 2026
First PostedJun 13, 2016
Enrollment StartMay 31, 2016
Primary CompletionJul 1, 2019
Study CompletionAug 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.1 years ago
Interventions
indomethacin suppositorydrug
100mg rectal indomethacin 30min before ESWL
Glycerin Suppositorydrug
30min before ESWL